Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH.
Cho BC, et al. Among authors: kim yj, kim h, kim sk, kim jh.
J Clin Oncol. 2007 Jun 20;25(18):2528-33. doi: 10.1200/JCO.2006.10.4166.
J Clin Oncol. 2007.
PMID: 17577030
Clinical Trial.